Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826-833

Dreyling M: Biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book. 2014;34:191-8.

Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and Follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71.

Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770-8

Dreyling M, Lenz G, Hoster E, van Hoof A, et al.: Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell Transplantation in first remission significantly prolongs progression - free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105: 2677-2684, 2005. DOI 10.1182/blood-2004-10-3883


Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 Pinnacle study. Ann Oncol. 2009 Mar;20: 520-525. DOI: 10.1093/annonc/mdn656

Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75.

 Hess G, Herbrecht R, Romaguera J, et al: Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol. 2009

Hoster E, Rosenwald A, Berger F et al.  Prognostic Value of KI-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34(12):1386-

Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31

Martin P, C hadburn A, Christos P, et al: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27: 1209-1213, 2009. DOI: 10.1200/JCO.2008.19.6121

Robak T, Jin J, Pylypenko H et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Lancet Oncol. 2018 Oct 18.

Rummel MJ, Niederle N, Maschmeyer Get al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10.

Wang M, Fowler N, Wagner-Bartak N et al. oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep;27(9):1902-9.